Crispr Therapeutics AG Revenue 2015–2025
Crispr Therapeutics AG annual/quarterly revenue history and growth rate from 2015 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Crispr Therapeutics AG revenue for the quarter ending March 31, 2026 was 1.5 M, a 68.55% increase year-over-year.
- Crispr Therapeutics AG revenue for the twelve months ending March 31, 2026 was 4.1 M, a 152.87% increase year-over-year.
- Crispr Therapeutics AG annual revenue for 2025 was 3.5 M, a 90.59% decrease from 2024.
- Crispr Therapeutics AG annual revenue for 2024 was 37.3 M, a 89.95% decrease from 2023.
- Crispr Therapeutics AG annual revenue for 2023 was 371.2 M, a 30885.48% increase from 2022.
- Crispr Therapeutics AG annual revenue for 2022 was 1.2 M.
Crispr Therapeutics AG (CRSP) — Frequently Asked Questions
Crispr Therapeutics AG (CRSP) is a publicly traded US company. It has a market capitalization of $4.52B. In fiscal 2025 it reported revenue of $4M and net income of -$582M. Explore CRSP's stock price, financial statements, earnings history, margins and key ratios below.
What is Crispr Therapeutics AG's market cap?
Crispr Therapeutics AG (CRSP) has a market capitalization of $4.52B.
What is the CRSP stock price?
CRSP trades at $50.28 (+1.70% on the day).
How much revenue does Crispr Therapeutics AG make?
Crispr Therapeutics AG reported revenue of $4M in fiscal 2025.
Is CRSP profitable?
In fiscal 2025, Crispr Therapeutics AG reported net income of -$582M.